Articles tagged with Esophageal Cancer
Researchers found that tumor-resident T-cell receptor sequences showed high complementarity with the cancer testis antigen DDX53, suggesting an immune response that selects for DDX53-negative cells. This association was correlated with worse disease-free survival rates, highlighting a potential early esophageal cancer antigen.
A UCLA study found that hospitals with high patient diversity are less likely to offer core cancer services, including hospice care, chemotherapy, and robotic surgery. The lack of these resources can impact treatment quality and outcomes for patients diagnosed with cancer.
Men who are overweight or obese at age 18 have a higher risk of developing 17 different cancers later in life. Higher BMI is also associated with an increased risk of mortality after cancer diagnosis for certain types of cancer.
A team of researchers at Case Western Reserve University has identified a genetic defect in Caveolin-3 that increases the risk of developing esophageal adenocarcinoma. The discovery could lead to early screening, lifestyle modifications, and targeted treatments for individuals with a family history of the disease.
A large-scale study from three Nordic countries shows that the majority of patients with reflux disease do not have a higher risk of cancer. Only those with changes in the oesophageal mucosa are at increased risk.
A novel liquid biopsy technology developed by UCSC Assistant Professor Daniel Kim's lab leverages RNA 'dark matter' to enhance cancer diagnosis. The test detects both protein-coding and repetitive noncoding RNAs in the blood, showing improved sensitivity for early-stage cancer detection.
Patients with cancer who live in rural Pennsylvania counties are more likely to receive complex surgeries at high-volume hospitals due to their perceived better outcomes. However, for less complex surgeries, rural patients are less likely to opt for high-volume hospitals despite potential benefits from centralization.
Researchers discovered that nine percent of esophageal adenocarcinoma patients harbor cancer-predisposing gene mutations, which may trigger progression from Barrett's esophagus. This finding supports the idea that genetic testing can help risk-stratify EAC patients and potentially accelerate development of new treatments.
A large international database analysis found nearly a quarter of esophageal adenocarcinoma patients had normal endoscopies but were still diagnosed within a year. The study suggests using high-quality equipment, rigorous sampling protocols, and future research on biomarker panels to improve screening effectiveness.
Three University Hospitals and Case Western Reserve University research teams received $50,000 Collaborative Science Pilot Awards to explore innovative research projects. The awards aim to increase competitiveness and capacity for major external funding opportunities in key areas such as cancer, brain health and genetics.
Researchers have developed a new technique to generically treat several kinds of cancer, showing tumors grew almost three times less and survival rates reached 100% after just one injection. The method targets cancer cells with alpha radiation, sparing healthy tissue.
A new study found that obesity is associated with an increased risk of certain cancers, with stronger links in female patients for gallbladder and endometrial cancer. The study also revealed differential effects between sexes on colorectal, esophageal, and liver cancer.
Researchers at Case Western Reserve University have identified a panel of long intergenic non-coding RNAs that are
The HALP score, a novel immune-nutritional marker, has been linked to prognostic ability in different cancer types. It integrates indicators of immune status and nutritional status, showing promise as a cost-effective biomarker.
The use of AI is improving diagnostic accuracy for digestive cancers, but challenges in data sharing and standardization hinder its widespread application. Researchers surveyed recent applications of AI to these deadly cancers, finding that AI can automate complex processes and detect patterns not visible to humans.
Researchers identified key metabolic pathways in tumor-associated macrophages that contribute to cancer development and progression. Targeting these pathways may provide a new perspective for immunotherapy-based cancer treatments.
Johns Hopkins researchers have developed a three-dimensional organoid model derived from human tissue to study gastroesophageal junction (GEJ) cancer. The dual knockout of genes in the model has identified key biological targets for treating GEJ cancers with existing drugs.
A study published in Nature reveals that cancer stem cells' miscommunication with their environment can trigger a self-perpetuating series of events leading to malignancy. Leptin signaling plays a surprising role in this process, which could be blocked to prevent tumor progression.
The ESMO Asia Congress 2022 will focus on the latest scientific and clinical advances in oncology, with a special emphasis on the Asia-Pacific region. Media representatives can register for coverage through the official media registration form.
A study published in JCI Insight has found that genetic variation plays a crucial role in the racial disparity of esophageal cancer cases. Researchers used artificial intelligence-guided tools to pinpoint a specific type of immune cell as the disease driver, and a protective genetic factor associated with African Americans.
A study by Case Western Reserve University has identified a promising path to developing therapies for esophageal tumors. The research team linked the TGFβ-pathway, a cell signaling mechanism, to tumor development and found that a protein-coding gene called HNF4α is a predictive biomarker of cancer.
A team of researchers at Case Western Reserve University has discovered a cell signaling pathway responsible for the development of esophageal adenocarcinomas. The Ephrin B2 (EphB2) Tyrosine kinase pathway is activated during cancer growth and regulates the behavior of normal esophageal cells, making it an attractive therapeutic target.
Researchers discovered PDE5 inhibitors can reverse chemotherapy resistance by targeting cancer-associated fibroblasts, potentially shrinking oesophageal tumours more than chemotherapy alone. The treatment is already proven to be safe and well-tolerated, with promising results in a phase I/II clinical trial.
Researchers at Tokyo Medical and Dental University have developed a liquid biopsy that can determine if an esophageal cancer patient will respond to certain treatments. The biopsy uses a panel of mRNAs and microRNAs to predict patient outcomes, with improved accuracy when combined with tumor size data.
Scientists have discovered that oxidative stress, a process disrupting genetic code by damaging DNA, is the culprit behind inflammation's link to cancer. The study provides crucial insights into roles of inflammation and oxidative stress in certain cancers.
Research found a significant increase in esophageal cancer and Barrett's esophagus among middle-aged adults, with rates nearly doubling between 2012 and 2019. The study suggests an urgent need for earlier endoscopic screening in this age group, particularly those with multiple risk factors.
A minimally invasive device combined with molecular biomarkers has shown a 90% success rate in detecting esophageal squamous cell carcinoma, the predominant subtype of esophageal cancer. Early detection is crucial to improve survival rates, as symptoms often become apparent too late for effective treatment.
A clinical trial found that adding immunotherapy to standard treatment increased the likelihood of complete tumor eradication in patients with high PD-L1 expression. The combination could become a new standard of care if confirmed in larger trials.
Adults aged 45-64 experienced a nearly doubled rate of esophageal cancer and a 50% increase in Barrett's esophagus between 2012 and 2019. Researchers recommend more frequent screening for middle-aged patients with multiple risk factors.
Patients with stage II/III esophageal cancer who received delayed surgery had a relative survival rate that was almost half that of patients who underwent early surgery. Early-stage cancer patients did not experience significant differences in survival rates between those who received immediate versus delayed surgery.
Researchers found that DNA changes in patients with precancerous Barrett's esophagus that presage esophageal cancer can be spotted years before cancer develops. The characteristic changes include rearrangements of large chunks of DNA and damage to the tumor-suppressing gene TP53.
Researchers at the Lewis Katz School of Medicine defined 11 subsets of cells found in esophageal tissue using single cell gene-expression profiling. This study could help clinicians diagnose or treat certain types of cancer by identifying functional cell types contributing to cancer progression.
The study reveals a narrowing gap between cancer profiles in China and the USA, with converging trends in lung, breast, and colorectal cancers. China's cancer burden is expected to rise, while the US has seen reduced rates since the 1990s due to effective prevention strategies.
A moderate exercise programme was shown to improve chemotherapy success rates and reduce negative side effects in oesophageal cancer patients. The study found that exercise can be safely included as part of cancer treatment, potentially benefiting more patients.
The NRG-RTOG 1010 clinical trial found that adding trastuzumab to chemoradiation and surgery did not improve disease-free survival for HER2-positive esophageal adenocarcinoma patients. Despite this, the study highlights future research opportunities to explore combining trastuzumab with other HER2-targeting agents.
Barrett's esophagus is caused by long-term GERD, which leads to changes in cells where the stomach and esophagus meet. Researchers found that stomach cells adopting intestinal cell qualities may be a key factor in its development.
The study evaluated outcomes of minimally invasive esophagectomy compared to open esophagectomy in 6000 ESCC patients over 10 years. MIE was found to be an effective treatment option even for large tumors, expanding its indicated population.
Researchers found that high levels of immune cells in tumors correlate with better outcomes for esophageal cancer patients. The study used the Immunoscore to evaluate tumor-infiltrating lymphocytes and found a strong association between high scores and long-term survival rates.
Researchers discovered that mutant clones in the normal human oesophagus outcompete and eliminate emerging tumours, preventing them from growing. This study sheds light on how cancer develops and could lead to new ways to prevent early tumours from becoming cancers.
A new study finds oesophageal cancer cases have tripled in under 50s, with increases attributed to lifestyle-related risk factors such as smoking and poor diet. The study also shows improved relative survival rates for younger patients, highlighting the importance of early diagnosis and treatment.
Abnormal cells that develop into oesophageal cancer start as stomach cells and can be reprogrammed to adopt an intestinal identity. The study identified two key genes, MYC and HNF4A, that switch tissue identity from stomach to intestinal cells.
A systematic review of epidemiological studies found that muscle strengthening exercises associated with aerobic activities can significantly reduce cancer mortality. The analysis suggested that strength training twice a week can protect against cancer, with the benefit being even greater when combined with aerobic activities.
A new treatment sequence for esophageal cancer may improve patient outcomes by treating microscopic disease first. The approach adds chemotherapy for two to three months before radiation and surgery, potentially reducing mortality rates.
Researchers found that high levels of certain blood lipids are associated with a higher risk of developing esophageal cancer in individuals with a family history of the disease. The study suggests considering 'stratified' analysis to better understand the relationship between serum lipids and cancer.
Scientists discovered esophageal cancers reactivate ancient retroviruses hidden in the human genome, which can make cancer more susceptible to immunotherapy. Researchers found a specific enzyme called ADAR1 degrades toxic double-stranded RNAs produced by ERV expression, and inhibiting it may enhance treatment efficacy.
A new commentary suggests that more extensive use of minimally invasive non-endoscopic tests for Barrett's esophagus (BE) screening could lead to better early detection and prevention of esophageal adenocarcinoma, a deadly form of cancer. BE is often asymptomatic, but endoscopic treatment can reduce the risk of progression to cancer.
Researchers identify patients at high risk for esophageal adenocarcinoma through aneuploidy detection in Barrett's Esophagus, allowing for early intervention. The new method, RealSeqS, is quick, cost-effective, and can process hundreds of samples, making it ideal for clinical implementation.
A new technique for sampling and testing cells from Barrett's esophagus patients can detect specific chromosomal alterations, including the presence of esophageal adenocarcinoma. The approach combines esophageal brushing with massively parallel sequencing to provide an accurate assessment of disease stages and identify high-risk patients.
A large prospective study found a significant link between acid reflux disease and the development of cancers in the larynx and esophagus. The study, published in the American Cancer Society journal CANCER, estimated that approximately 17% of these cancers are associated with GERD.
A new study found that elderly patients with locally advanced esophageal and esophagogastric junction cancer can achieve similar outcomes as younger patients when receiving recommended multimodal therapy. The therapy regimen includes initial chemoradiotherapy followed by surgical resection.
Researchers found that certain oral pathogens are more prevalent in esophageal cancer patients, particularly in dental plaque and saliva. The study suggests that these pathogens may be associated with a high risk of esophageal cancer and could form the basis of future screening methods.
Researchers found that serum albumin and geriatric nutritional risk index (GNRI) are independent prognostic factors for cancer-specific survival in patients with esophageal squamous cell carcinoma. Low GNRI levels were significantly associated with worse survival outcomes, particularly in early-stage disease.
A recent study found that extrachromosomal DNA (ecDNA) is common in human cancer and drives poor patient outcomes. ecDNA is a circular unit of DNA containing functional genes located outside cells' chromosomes, which rapidly replicate within cancer cells causing high numbers of oncogene copies.
A new pathological grading system evaluates the therapeutic effect of neoadjuvant chemotherapy for metastatic lymph nodes in esophageal cancer patients. The system predicts recurrence and prognosis more accurately than conventional methods.
Researchers at Baylor Scott & White Research Institute receive NIH funding to investigate the molecular mechanisms that link GERD to Barrett's esophagus and cancer. The team aims to identify strategies to prevent EMT, a process that promotes cancer cell survival.
A new Canadian guideline found no benefit to routine screening for esophageal adenocarcinoma (EAC) and its precursor conditions in patients with chronic gastroesophageal reflux disease (GERD). The guideline recommends physicians continue current practice, not screening patients without alarm symptoms.
A new study found that Black patients with early-stage esophageal cancer are less likely to receive life-saving surgery, contributing to their higher mortality rates. The study, which analyzed data from over 60,000 patients, suggests that education and targeted interventions are needed to address these disparities.
A recent randomized controlled trial found that landiolol hydrochloride administration reduced the incidence of postoperative atrial fibrillation after esophagectomy for esophageal cancer. However, this did not impact overall survival in patients with esophageal cancer.
The NRG Oncology trial RTOG 1010 found that adding trastuzumab to neoadjuvant trimodality treatment did not improve disease-free survival for patients with HER2-positive local and locally advanced esophageal adenocarcinoma. The study also showed no significant differences in treatment-related toxicity between the two arms.
Researchers delivered an ALDH2 gene to mice with the deficiency, using a virus-mediated approach. The treated mice showed no signs of the acute abnormalities or chronic disorders normally associated with ethanol exposure in ALDH2 deficiency.